KYNAMRO Risk Evaluation and Mitigation Strategy (REMS)

The FDA has required a REMS program for KYNAMRO so that the benefits of the drug outweigh the risks to patients.

The purpose of KYNAMRO REMS is to:

- Educate prescribers about:
  - the risk of hepatotoxicity associated with the use of KYNAMRO
  - the need to monitor patients during treatment with KYNAMRO as per product labeling
- Restrict access to therapy with KYNAMRO to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia (HoFH)

Only health care providers trained, enrolled and thereby certified in KYNAMRO REMS may prescribe KYNAMRO

For health care providers to become certified in KYNAMRO REMS:

1. **Train**
   - Click to open and review all of the educational materials below, including the question-and-answer section of the Prescriber Training Slide Set.

   - **Prescriber Training Slide Set**
   - **Summary of Monitoring Recommendations**
   - **Prescribing Information**

2. **Enroll**
   - Download and complete the Prescriber Enrollment Form below.
   - Fax completed form to 877-778-9006 or scan and email to KynamroREMS@genzyme.com

For every new prescription for KYNAMRO:

**RX**

**Prescribe**
- For every new prescription for KYNAMRO, REMS-Certified Prescribers must use the Prescription Authorization Form below.
- Download, complete, and Fax completed form to 877-778-9008, or email to KynamroREMS@genzyme.com

This site is intended for United States residents only.

Copyright ©2015 Genzyme Corporation, a Sanofi company. All rights reserved. KYNAMRO and Genzyme are registered trademarks of Genzyme Corporation.